The compound has been indeed detected in the plasma of healthy young adults using body-lotion cosmetics

in concentrations up to 4.1 μg/L ( Hutter et al., 2005). However, even at such a concentration, galaxolide should not substantially interfere with the endogenous ligand progesterone (Kexp = 3.7 nM, Kcalc = 22 nM). False-positive predictions may, thus, occur in all cases where the kinetic stability of a protein–ligand complex is lower than the thermodynamic selleck chemical and—probably more relevant—when the ADME predisposition is unfavorable. We therefore plan to augment our technology with a series of corresponding pre-filters in the near future. False-negative predictions may occur for at least three reasons. Firstly (and most frequently), learn more when the adverse effect of a compound is triggered mechanisms other than those currently tested in the VirtualToxLab. Examples include Ochratoxin A (OcA), a

well known mycotoxin which does not significantly bind to any of our target proteins and is associated with a toxic potential of 0.519 suggesting only a moderate toxicity. While the toxic mechanism of OcA has not yet been fully disclosed (see, for example, Sorrenti et al., 2013), a critical step of the toxic pathway is the long residence time of OcA at the plasma protein serum albumin. Secondly, a toxic response may be triggered by a metabolite rather than by the parent compound. While our technology does not automatically generate feasible metabolites (several pieces of third-party software have been developed for this very purpose), at least primary metabolites should always be tested along with a parent compound.

In an earlier study, we have analyzed the activity of cyclo-diBA (a condensation product of glycidyl ether and bisphenol A) metabolites—a compound that is unintentionally Ureohydrolase formed as by-product during the coating of food cans and, due to its lipophilic character, migrates from the epoxy resin of the coating into the fatty tissues e.g., of canned fish ( Biedermann et al., 2013). Another example includes the metabolites of the mycotoxin zearalenone, which are known to display estrogenic activity (see, for example, Takemura et al., 2007 and Metzler et al., 2010). While the VirtualToxLab suggests a toxic potential of 0.409 for the parent compound, one of its metabolites, β-zearalanol, is estimated at 0.504. Fig. 13 compares the identified binding modes for the parent compound zearalenone and its metabolite β-zearalanol. Another reason for a false-negative prediction may lie in the fact that our sampling of the ligand at the protein’s binding site while extensive (cf. above) is not exhaustive. Thus, the correct binding mode may simply not been have generated within the 6000–12,000 trials. Finally, molecules that trigger a substantial induced fit (i.e., including changes in the protein’s main-chain conformation) are currently beyond our computational time scale.